Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: gcrispin who wrote (40427)	12/7/2010 1:04:11 AM
From: armi	Respond to of 78744

Pharm is generally a sector that I tend to stay cautious in. A company can live and die by patents in this field and unless they have a substantial part of their sales in something else like JNJ where they have a lot of sales in Consumer Health(btw. JNJ is at an okay entry price, by no means value but not expensive too!). I haven't read into Merck but by looking at their financial statements, Merck has a billion more in shares outstanding and sold a lot of their Treasury Stock as well. Doing a quick google search, I noticed they paid $49.6 billion for rival Schering-Plough which is probably a good deal considering their is a lot of praise for the deal.